Venus Remedies Limited has informed the Exchange regarding 'Grant of Marketing Authorisation in Indonesia'.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 3.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies has received marketing authorisation from the Indonesian drug regulatory authority for its antibiotic combination Ceftazidime + Avibactam, used to treat serious multi-drug resistant infections such as complicated intra-abdominal and urinary tract infections. This is the company's first marketing approval for this product in Indonesia. Indonesia is described as one of the largest pharmaceutical markets in Southeast Asia, with antibiotics being a major segment. The company plans to commercialise the product using its existing distribution partnerships in the region. The move is part of its broader strategy to expand its footprint in South-East Asia and grow its portfolio of high-barrier-to-entry therapies.
Positive for the stock — opens a new revenue stream in a large, strategically important South-East Asian market, though actual financial contribution will depend on how quickly sales ramp up through existing distribution channels.